Clinical Trial News Archive - May 2022
May 2, 2022
May 3, 2022
- Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular Degeneration
- Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma
May 4, 2022
May 5, 2022
- Johnson & Johnson Updates U.S. COVID-19 Vaccine Fact Sheet
- Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
May 6, 2022
- Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi
- NIH Launches Clinical Trial of Epstein-Barr Virus Vaccine
May 9, 2022
May 10, 2022
- Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
- Results from Trial on Sufentanil Sublingual Tablet Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia
- UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis
May 11, 2022
May 12, 2022
- NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality
- Vaccine for Rare But Deadly Mosquito-Borne Viruses Shows Promise in Clinical Trial
- New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
May 15, 2022
- PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide Used as Rescue Medicine Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients with Asthma
- Boehringer Ingelheim’s Latest Investigational Treatment BI 1015550 Slowed Lung Function Decline in People Living with Idiopathic Pulmonary Fibrosis
May 16, 2022
- Galera Announces Plan to Submit Avasopasem NDA by Year End
- Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
- Diadem Announces Publication of Clinical Study Confirming Its AlzoSure Predict Blood Test Can Accurately Predict Progression to Alzheimer's Disease Six Years Before Diagnosis
- FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
- Scientists Identify Characteristics to Better Define Long COVID
- PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
May 17, 2022
- First patient randomized in Phase 2 trial in head and neck cancer
- Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
May 18, 2022
- Axsome Therapeutics Announces Publication of Pivotal Ascend Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of Psychiatry
- Pre-clinical findings support the potential use of RhoVac's drug candidate, onilcamotide, across several cancers
May 19, 2022
- MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
- Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
May 23, 2022
- Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
- Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
- New Data Reinforces Effectiveness of Dual Pathway Inhibition with Xarelto plus Aspirin in Patients with Coronary Artery Disease and/or Peripheral Artery Disease
May 24, 2022
- Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
- SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors
- Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
- Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
- Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
May 25, 2022
- Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions
- Pharmazz Inc. Announces Positive Results of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke
- Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
- NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19
- Codagenix Initiates Phase 1 Evaluation of Intranasal Vaccine CoviLiv for Use as COVID-19 Booster
May 26, 2022
- New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People with Aggressive Lymphoma
- Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
- Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
- Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
- Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
May 27, 2022
- INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo (cemiplimab) in Patients with Newly Diagnosed GBM
- New Pivotal Data Demonstrate Clinical Benefit of Roche’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People with Aggressive Lymphoma
May 30, 2022
May 31, 2022
- Novavax Initiates Phase 3 Trial of its COVID-19 Omicron Strain Vaccine as a Booster
- VILTEPSO (viltolarsen) injection: Long-Term Efficacy and Safety Data Published in the Journal of Neuromuscular Diseases
- Amgen Announces Positive Topline Phase 2 Data For Investigational Olpasiran in Adults with Elevated Lipoprotein(a)
- Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
Clinical trial results archive
- 2025
- January, February, March, April
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.